Torsemide
Unchecked
Torsemide
Demadex, Soaanz
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Common uses
Volume overload in heart failure0, Hepatic edema/ascites0, Edema in CKD0, Hypertension (selected cases)0
Pharmacy
Starting dose
10-20 mg PO/IV once daily; titrate by clinical response. 1:1 IV to PO conversion (unlike furosemide's 1:2)
Preparations
5, 10, 20, 100 mg tablets; 10 mg/mL IV
US FDA Max
200 mg/d typical practical ceiling
Pharmacology
Routes
Oral, IV
Onset
PO 1 hour; IV 10 minutes
Duration
6-8 hours
Half-life
3-4 hours (similar between PO and IV due to high oral bioavailability)[1]
Bioavailability
~80% (oral; predictable absorption — a substantive practical advantage over furosemide whose oral absorption is 10-100% variable)[1]
Pregnancy
Avoid where possible; class concerns as for other loop diuretics.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Torsemide blocks the Na+/K+/2Cl- cotransporter (NKCC2) on the apical membrane of thick ascending limb cells, producing brisk natriuresis, kaliuresis, and free-water clearance like furosemide but with a more reliable oral pharmacokinetic profile.0 The TRANSFORM-HF trial (2023) found no all-cause mortality difference between torsemide and furosemide in heart failure, although torsemide remains pharmacologically preferred where furosemide oral absorption is unreliable[1].
References
[edit | edit source]- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Demadex (torsemide), Roche/Meda, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020136s019,020137s018lbl.pdf